SAMS Response to National Biotechnology and Biomanufacturing Initiative

WASHINGTON, September 12, 2022. – The Securing America’s Medicines and Supply (SAMS) coalition applauds the Biden-Harris Administration for its Executive Order (EO) launching a National Biotechnology and Biomanufacturing Initiative to advance domestic supply chains. SAMS also encourages the Administration to make targeted investments in late-stage research and development (R&D) to ensure the commercial scale-up and manufacturing of novel technologies. 

“SAMS commends the Administration for taking up the mantle and working to ensure that what’s invented in America is made in America,” said David Sanders, Executive Director of SAMS and Vice President of Government Affairs and Policy at Coherus BioSciences. “SAMS has paid close attention to the initiatives coming out of the Administration and Congress. We are proud to work with our member companies, industry stakeholders, and allied countries to advocate for a cohesive, international strategy to de-risk the United States from a vulnerable medical supply chain. This EO is a major step in the right direction.” 

“Our members are representative of the thousands of companies accelerating product development for a wide range of indications – and they are doing so thanks to novel biomanufacturing methods. Going forward, it’s time to make strategic federal investments through these initiatives to expand domestic manufacturing, create jobs, and protect American patients.” 


About Securing America’s Medicines and Supply 

Securing America’s Medicines and Supply (SAMS) is a multi-industry coalition of companies with the mission to strengthen the security of the medical supply chain in the United States. SAMS seeks to drive implementation of legislation and regulation to reward and foster U.S.-made manufacturing of important pharmaceutical products, devices, and supplies. SAMS supports U.S. patients, domestic healthcare security, and U.S. jobs.